Publication:
A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels

dc.contributor.coauthorKong, Bo
dc.contributor.coauthorWu, Weiwei
dc.contributor.coauthorValkovska, Nataliya
dc.contributor.coauthorJäger, Carsten
dc.contributor.coauthorHong, Xin
dc.contributor.coauthorNitsche, Ulrich
dc.contributor.coauthorFriess, Helmut
dc.contributor.coauthorEsposito, Irene
dc.contributor.coauthorKleeff, Jörg
dc.contributor.coauthorMichalski, Christoph W.
dc.contributor.departmentN/A
dc.contributor.kuauthorErkan, Murat Mert
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid214689
dc.date.accessioned2024-11-09T23:07:27Z
dc.date.issued2015
dc.description.abstractHNF1 homeobox A (HNF1A)-mediated gene expression constitutes an essential component of the secretory pathway in the exocrine pancreas. Melanoma inhibitory activity 2 (MIA2), a protein facilitating protein secretion, is an HNF1A target. Protein secretion is precisely coordinated by the endoplasmic reticulum (ER) stress/unfolded protein response (UPR) system. Here, we demonstrate that HNFA and MIA2 are expressed in a subset of human PDAC tissues and that HNF1A induced MIA2 in vitro. We identified a common germline variant of MIA2 (c.A617G: p.I141M) associated with a secretory defect of the MIA2 protein in PDAC cells. Patients carrying MIA2I141M survived longer after tumor resection but the survival benefit was restricted to those patients who received adjuvant chemotherapy. The MIA2I141M variant was associated with high expression of ER stress/UPR genes – in particular those of the ERN1/XBP arm – in human PDAC samples. Accordingly, PDAC cell lines expressing the MIA2I141M variant expressed high levels of ERN1 and were more sensitive to gemcitabine. These findings define an interaction between the common MIA2I141M variant and the ER stress/UPR system and specify a subgroup of PDAC patients who are more likely to benefit from adjuvant chemotherapy. © 2015, Nature Research. All rights reserved.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue1
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.volume5
dc.identifier.doi10.1038/SREP08109
dc.identifier.issn2045-2322
dc.identifier.linkhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84959373394anddoi=10.1038%2fSREP08109andpartnerID=40andmd5=84dc5fc0561375b815d285828537e33d
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-84959373394
dc.identifier.urihttp://dx.doi.org/10.1038/SREP08109
dc.identifier.urihttps://hdl.handle.net/20.500.14288/9149
dc.keywordsAdenocarcinoma
dc.keywordsAdenocarcinoma
dc.keywordsAntimetabolites, Antineoplastic
dc.keywordsAntimetabolites, Antineoplastic
dc.keywordsCarcinoma, Pancreatic ductal
dc.keywordsCarcinoma, Pancreatic ductal
dc.keywordsChemotherapy, Adjuvant
dc.keywordsChemotherapy, Adjuvant
dc.keywordsDeoxycytidine
dc.keywordsDeoxycytidine
dc.keywordsDrug resistance, Neoplasm
dc.keywordsDrug resistance, neoplasm
dc.keywordsEndoplasmic reticulum stress
dc.keywordsEndoplasmic reticulum stress
dc.keywordsEndoribonucleases
dc.keywordsEndoribonucleases
dc.keywordsGene expression
dc.keywordsGene expression
dc.keywordsGenetic variation
dc.keywordsHepatocyte nuclear factor 1-alpha
dc.keywordsHepatocyte nuclear factor 1-alpha
dc.keywordsHumans
dc.keywordsHumans
dc.keywordsPancreatic neoplasms
dc.keywordsPancreatic neoplasms
dc.keywordsPrognosis
dc.keywordsPrognosis
dc.keywordsProtein
dc.keywordsSerine-threonine kinases
dc.keywordsTreatment outcome
dc.keywordsTumor suppressor proteins
dc.languageEnglish
dc.publisherNature
dc.sourceScientific Reports
dc.subjectMedicine
dc.titleA common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-2753-0234
local.contributor.kuauthorErkan, Murat Mert

Files